Affimed N.V. (AFMD) News

Affimed N.V. (AFMD): $1.24

-0.04 (-3.13%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AFMD to Watchlist
Sign Up

Industry: Biotech


Ranked

of 401

in industry

Filter AFMD News Items

AFMD News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

AFMD News Highlights

  • For AFMD, its 30 day story count is now at 6.
  • Over the past 16 days, the trend for AFMD's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • AB, DRUG and HOUR are the most mentioned tickers in articles about AFMD.

Latest AFMD News From Around the Web

Below are the latest news stories about AFFIMED NV that investors may wish to consider to help them evaluate AFMD as an investment opportunity.

Volatile Stock to Watch: Compugen Ltd. (NASDAQ:CGEN 2.15%), Affimed N.V. (NASDAQ:AFMD 0.86%)

Compugen Ltd. (NASDAQ:CGEN) with the stream of 2.15% also noticed, India Affimed N.V. (NASDAQ:AFMD) encountered a rapid change of 0.86% in the last hour of Tuesday’s trading session. Compugen Ltd. … The post Volatile Stock to Watch: Compugen Ltd. (NASDAQ:CGEN 2.15%), Affimed N.V. (NASDAQ:AFMD 0.86%) appeared first on Stocks Equity .

Stock Equity | January 25, 2023

Do investors need to be concerned about Affimed N.V. (AFMD)?

In Monday’s session, Affimed N.V. (NASDAQ:AFMD) marked $1.16 per share, down from $1.22 in the previous session. While Affimed N.V. has underperformed by -4.92%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AFMD fell by -71.98%, with highs and lows ranging from $5.10 to $1.03, whereas […]

US Post News | January 24, 2023

Was anything positive for Affimed N.V. (AFMD) stock last session?

Affimed N.V. (NASDAQ:AFMD) marked $1.15 per share on Tuesday, up from a previous closing price of $1.14. While Affimed N.V. has overperformed by 0.88%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AFMD fell by -73.92%, with highs and lows ranging from $5.10 to $1.03, whereas […]

US Post News | January 18, 2023

These Numbers Reveal How Powerful Affimed N.V. (NASDAQ: AFMD) Stock Is

The trading price of Affimed N.V. (NASDAQ:AFMD) closed higher on Friday, January 13, closing at $1.14, 0.88% higher than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $1.085 and $1.15. In examining the 52-week price action we see that the stock hit a 52-week high … These Numbers Reveal How Powerful Affimed N.V. (NASDAQ: AFMD) Stock Is Read More »

Stocks Register | January 17, 2023

Affimed N.V. (NASDAQ: AFMD) Fell -351.33% From Highs, What Does The Future Hold?

Affimed N.V. (NASDAQ:AFMD)’s traded shares stood at 2.18 million during the last session, with the company’s beta value hitting 2.37. At the close of trading, the stock’s price was $1.13, to imply an increase of 5.61% or $0.06 in intraday trading. The AFMD share’s 52-week high remains $5.10, putting it -351.33% down since that peak … Affimed N.V. (NASDAQ: AFMD) Fell -351.33% From Highs, What Does The Future Hold? Read More »

Marketing Sentinel | January 13, 2023

Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13

AFM13 combination with Artiva’s AB-101 NK cells: Received written feedback to pre-investigational new drug (IND) meeting request which supports plan for IND filing in H1 2023 and initiation of clinical study during 2023AFM24: Data updates from the three AFM24 ongoing studies are expected at scientific conferences in Q2/Q3 2023AFM28: Clinical trial application (CTA) cleared in France and Spain with additional filings in European countries pending; initiation of phase 1 study is expected in Q2 202

Yahoo | January 9, 2023

Is Affimed N.V. (NASDAQ:AFMD) stock a better investment at this time?

Affimed N.V. (AFMD)’s stock has witnessed a price hike of 3.63% from the previous close with its current price standing at $1.28. Its current price is -77.73% under its 52-week high of $5.77 and 24.76% more than its 52-week low of $1.03. Based on the past 30-day period, the stock price is -40.23% below the […]

US Post News | January 3, 2023

Understanding Affimed N.V. (NASDAQ: AFMD)’s Growth Potential

Affimed N.V. (NASDAQ:AFMD) shares, rose in value on Thursday, December 29, with the stock price up by 3.51% to the previous day’s close as strong demand from buyers drove the stock to $1.18. Actively observing the price movement in the recent trading, the stock is buoying the session at $1.14, falling within a range of … Understanding Affimed N.V. (NASDAQ: AFMD)’s Growth Potential Read More »

Stocks Register | December 29, 2022

Investors in Affimed (NASDAQ:AFMD) have unfortunately lost 80% over the last year

Even the best investor on earth makes unsuccessful investments. But it's not unreasonable to try to avoid truly...

Yahoo | December 28, 2022

Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia

AFM28 monotherapy receives authorization of a Clinical Trial Application (CTA) for the phase 1 study by the French National Agency for the Safety of Medicines and Health Products (ANSM)Initiation of AFM28 clinical development in the first half of 2023 on track HEIDELBERG, Germany, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced to

Yahoo | December 22, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 1.0812 seconds.